Scientists track new schizophrenia Drug's journey through the body
NCT ID NCT07455084
Summary
This early-stage study aims to understand how the body absorbs, breaks down, and eliminates a potential new oral medication for schizophrenia. Eight healthy adult men will receive a single dose containing a tiny, safe amount of radioactive tracer to track the drug's path. The main goal is to learn how the drug moves through the body and to check for any safety concerns.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Celerion, Inc.
Lincoln, Nebraska, 68502, United States
Conditions
Explore the condition pages connected to this study.